Update from NICE re Nusinersen
30 April 2019
Following the meeting on 6 March 2019, the appraisal committee asked NHS England and Biogen to enter into commercial discussions to see whether a managed access arrangement could be agreed for nusinersen consistent with NICE’s framework for determining cost effectiveness.
The outcome of these discussions and the consequences for guidance development for this topic will be considered by the committee on Wednesday 8th May. Given the nature of the discussion, this will be held in private.